-
AstraZeneca AB on its US$2-billion acquisition of Fusion Pharmaceuticals Inc.
-
venBio Partners LLC on its C$23-million minority investment in 35Pharma Inc.
-
Fonds de solidarité FTQ on its investment in NuChem Sciences Inc. in connection with NuChem’s acquisition of IniXium
-
Canadian Imperial Bank of Commerce, as agent, on DRI Healthcare Trust's credit agreement with a syndicate of lenders to establish a US$200-million revolving senior secured credit facility.
-
BioPharma Services Inc. on its acquisition by Think Research Corporation.
-
CRH Medical Corporation on its US$293-million acquisition by Well Health Technologies Corp.
-
Brooks Automation, Inc. on its acquisition of all of the shares of Trans-Hit Biomakers, Inc.
-
AbCellera Biologics Inc. on its US$555-million initial public offering.
-
GlaxoSmithKline on its agreement to provide the Government of Canada with up to 76 million doses of an adjuvanted COVID-19 vaccine, in collaboration with Medicago.
-
Forbius on its sale to Bristol Myers Squibb.
-
GlaxoSmithKline on its agreement to provide the Government of Canada with up to 72 million doses of an adjuvanted COVID-19 vaccine, in collaboration with Sanofi.
-
The Fertility Partners on the acquisition of two fertility clinics in Montréal (Clinique ovo) and Vancouver (Olive Fertility Centre), as well as securing approximately C$90-million in equity and debt financing.
-
GlaxoSmithKline Biologicals S.A. on its collaboration agreement with Medicago Inc. to develop, manufacture and distribute a COVID-19 candidate vaccine.
-
Correvio Pharma Corp. on its US$76-million proposed acquisition by Advanz Pharma.
-
Bristol Myers Squibb, parent company of Celgene Corporation, in Celgene’s sale of the worldwide rights to Otezla®.
-
Catalent Pharma Solutions Ltd., as Canadian counsel, on its purchase of all of the shares of Accucaps Industries Ltd. from Apotex Holdings Inc.
-
GlaxoSmithKline plc on its acquisition of Novartis AG's Vaccines business
-
Labomar Inc. on its acquisition of ImportFab s.r.l.
-
Janssen and the Kennedy Trust in a patent impeachment and infringement action related to Remicade (infliximab), a biologic treatment for rheumatoid arthritis; first patent infringement action in Canada relating to a subsequent entry biologic (a generic version of a biologic drug, also referred to as a biosimilar) (Janssen Inc. v. Pfizer Canada Inc.)
-
A large multi-national provider of electronic and electronical products, systems and solutions on the Canadian aspects of a multi-billion dollar sale of their global medical device business.
-
A private equity firm in connection with its acquisition and continuing consolidation of specialist dental and orthodontist practices across Canada.
-
Product liability class actions against leading multinational manufacturers and distributors of pharmaceutical, over-the-counter medicines and medical devices, including gastrointestinal medicines, contraceptive products and orthopaedic components; also involved in the national co-ordination of class action defence and strategy in other provinces including Quebec, Alberta, Nova Scotia and Saskatchewan.
-
Advising and assisting numerous pharmaceutical and device manufacturers and wholesalers and pharmacies on product approvals, pricing and reimbursement, product listing agreements, rebates, professional allowances, interchangeability of drugs, conflict of interest issues, procurement matters, and freedom of information requests relating to pricing.
-
Advising, drafting and negotiating industry-specific agreements, including those relating to collaborations, technology transfers, licences, and product manufacturing and distribution.
-
Drafting and negotiating Canadian clinical trial agreements for a major pharmaceutical company and a major medical devices company.
-
Preparing and prosecuting extensive intellectual property portfolios, including those relating to novel DNA markers for identifying certain forms of cancer, humanized antibodies for treatment against certain infections, prosthetic spinal implants, and the production of recombinant proteins and specialized in-situ delivery systems for such proteins.
-
Providing advice on Patented Medicine Prices Review Board issues, drug advertising, drug import and export issues, and clinical trials.
